Compare AAP & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | LQDA |
|---|---|---|
| Founded | 1929 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2002 | 2020 |
| Metric | AAP | LQDA |
|---|---|---|
| Price | $54.56 | $38.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $53.50 | $41.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 113.01 | 51.81 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $8,601,000,000.00 | $158,320,000.00 |
| Revenue This Year | $0.33 | $278.87 |
| Revenue Next Year | $2.50 | $57.13 |
| P/E Ratio | $77.42 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $30.48 | $11.85 |
| 52 Week High | $70.00 | $46.67 |
| Indicator | AAP | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 54.11 |
| Support Level | $51.90 | $31.75 |
| Resistance Level | $62.28 | $39.19 |
| Average True Range (ATR) | 2.18 | 1.93 |
| MACD | 0.43 | 0.29 |
| Stochastic Oscillator | 63.36 | 58.78 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.